Study Details

Back
Study ID 178-CL-102
Study Title A randomized, double-blind, parallel-group, active-controlled, multi-centre study to evaluate the long-term safety and efficacy of combination of Solifenacin Succinate with Mirabegron compared to Solifenacin Succinate and Mirabegron monotherapy in subjects with overactive bladder
Clinicaltrials.gov Identifier NCT02045862
Compound Name EB178 / mirabegron + solifenacin succinate
Medical Indication or Disease Overactive bladder
Study Sponsor Astellas Pharma Europe B.V.
Collaborator Not Applicable
Study Start Date 17-Mar-2014
Study Completion Date 08-Sep-2016
Clinical Study Result
Select the language
English
Plain Language Summary
Select the language
English

QUICK SEARCH

USEFUL LINKS